Within the past decade, the field of immunotherapy has revolutionized the treatment of many
cancers with the development and regulatory approval of various immune-checkpoint …

Recent advances in several areas are rekindling interest and enabling progress in the
development of therapeutic cancer vaccines. These advances have been made in target …

Effective anti-tumour immunity in humans has been associated with the presence of T cells
directed at cancer neoantigens, a class of HLA-bound peptides that arise from tumour …

Ovarian cancer is the deadliest gynecologic malignancy, with a 5-year survival rate of
approximately 47%, a number that has remained constant over the past two decades. Early …

Neoepitopes arising from amino acid substitutions due to single nucleotide polymorphisms
are targets of T cell immune responses to cancer and are of significant interest in the …

There is a need for transplantable murine models of ovarian high-grade serous carcinoma
(HGSC) with regard to mutations in the human disease to assist investigations of the …

Purpose: This was a study prospectively evaluating intratumoral T-cell responses to
autologous somatic mutated neoepitopes expressed by human metastatic ovarian cancers …

Adoptive cell therapy using T cell receptor-engineered T cells (TCR-T) is a promising
approach for cancer therapy with an expectation of no significant side effects. In the human …

Immunotherapy as a treatment for cancer is a growing field of endeavor but reports of
success have been limited for epithelial ovarian cancer. Overcoming the challenges to …

Cancer vaccines critically rely on the availability of targetable immunogenic cancer‐specific
neoepitopes. However, mutation‐based immunogenic neoantigens are rare or even non …